VANCOMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vancomycin, and when can generic versions of Vancomycin launch?
Vancomycin is a drug marketed by Xellia Pharms Aps, Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Pai Holdings Pharm, Strides Pharma, Watson Labs, Alkem Labs Ltd, Amneal, Aspiro, Avet Lifesciences, Eugia Pharma, Gland Pharma Ltd, Hikma, Hikma Pharms, Hospira, Hospira Inc, Knack, Medimetriks Pharms, Meitheal, Mylan Labs Ltd, Sagent Pharms, Sandoz, Sandoz Inc, Slate Run Pharma, Teva Pharms Usa, Zhejiang Novus Pharm, Samson Medcl, and Baxter Hlthcare. and is included in fifty-four NDAs. There are six patents protecting this drug.
This drug has forty-seven patent family members in twenty-nine countries.
The generic ingredient in VANCOMYCIN is vancomycin hydrochloride. There are twenty-two drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vancomycin
A generic version of VANCOMYCIN was approved as vancomycin hydrochloride by FRESENIUS KABI USA on March 17th, 1987.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VANCOMYCIN?
- What are the global sales for VANCOMYCIN?
- What is Average Wholesale Price for VANCOMYCIN?
Summary for VANCOMYCIN
| International Patents: | 47 |
| US Patents: | 5 |
| Applicants: | 29 |
| NDAs: | 54 |
| Raw Ingredient (Bulk) Api Vendors: | 37 |
| Clinical Trials: | 429 |
| Patent Applications: | 4,347 |
| Drug Prices: | Drug price information for VANCOMYCIN |
| What excipients (inactive ingredients) are in VANCOMYCIN? | VANCOMYCIN excipients list |
| DailyMed Link: | VANCOMYCIN at DailyMed |
See drug prices for VANCOMYCIN
Recent Clinical Trials for VANCOMYCIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Chang Gung Memorial Hospital | N/A |
| Hospital Universitario Evangelico de Curitiba | Phase 3 |
| University of Duhok | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for VANCOMYCIN
US Patents and Regulatory Information for VANCOMYCIN
VANCOMYCIN is protected by five US patents.
Patents protecting VANCOMYCIN
Glycopeptide compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS
Glycopeptide compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS
Glycopeptide compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Glycopeptide compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Glycopeptide compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Labs Ltd | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | INJECTABLE;INJECTION | 091554-001 | Sep 19, 2011 | AP | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan Labs Ltd | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | POWDER;INTRAVENOUS | 209481-006 | Jun 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hikma | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | INJECTABLE;INJECTION | 203300-002 | Aug 11, 2020 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VANCOMYCIN
See the table below for patents covering VANCOMYCIN around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
